Passage Bio Q2 net loss narrows to $9.4M; cash runway into Q1 2027

Passage BIO, Inc.

2025-Q2 EPS reported -$7.83

Cash, cash equivalents and marketable securities: $57.6M as of June 30, 2025 vs $91.8M a year ago; runway into Q1 2027.
Net loss of $9.4M ($2.96 per share) vs $16.0M ($5.09 per share) in Q2 2024 (adjusted for 1-for-20 reverse split).
Completed dosing of FTD-GRN Cohort 2 in upliFT-D study; all four patients treated with PBFT02.
Updated interim data: PBFT02 showed robust, durable CSF PGRN elevation and improved plasma NfL biomarker vs natural history.
Amended upliFT-D protocol submitted to trial sites and health authorities; plan to enroll Cohort 3 (FTD-GRN) and Cohort 4 (FTD-C9orf72).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.